Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More
Xconomy
MAY 4, 2018
Here’s a case study of how fast things can change in biopharma. Now, in the wake of one failed trial, the IDO train has skidded off the tracks. Now, in the wake of one failed trial, the IDO train has skidded off the tracks. Major drug makers were dealing, too.
52 
Let's personalize your content